These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19456205)

  • 21. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
    Yigit R; Massuger LF; Figdor CG; Torensma R
    Gynecol Oncol; 2010 May; 117(2):366-72. PubMed ID: 20144842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer.
    Chekmasova AA; Brentjens RJ
    Discov Med; 2010 Jan; 9(44):62-70. PubMed ID: 20102688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of ovarian cancer.
    Kirby TO; Huh W; Alvarez R
    Expert Opin Biol Ther; 2002 Apr; 2(4):409-17. PubMed ID: 11955278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy in ovarian cancer.
    Krishnan V; Berek JS; Dorigo O
    Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the immune microenvironment for ovarian cancer therapy.
    Blanc-Durand F; Clemence Wei Xian L; Tan DSP
    Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular therapy for ovarian cancer: experimental and clinical perspectives.
    Ingersoll SB; Ahmad S; Finkler NJ; Edwards JR; Holloway RW
    Curr Med Chem; 2012; 19(22):3787-93. PubMed ID: 22680925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed.
    Hu X; Bian C; Zhao X; Yi T
    Front Immunol; 2022; 13():1034903. PubMed ID: 36275669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
    Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
    Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
    Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
    J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunity and immune suppression in human ovarian cancer.
    Preston CC; Goode EL; Hartmann LC; Kalli KR; Knutson KL
    Immunotherapy; 2011 Apr; 3(4):539-56. PubMed ID: 21463194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigen-specific active immunotherapy for ovarian cancer.
    Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; Nijman HW
    Cochrane Database Syst Rev; 2014 Sep; (9):CD007287. PubMed ID: 25229990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.
    Cheng H; Ma R; Wang S; Wang Y; Li Y; Tang Z; Dou S; Wang Y; Zhu H; Ye X; Zhang T; Zhang Y; Li S; Zhao Y; Li Y; Cui H; Chang X
    Front Immunol; 2021; 12():707468. PubMed ID: 34408750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigen-specific active immunotherapy for ovarian cancer.
    Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief K; Nijman HW
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007287. PubMed ID: 20091627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.
    Zhang XW; Wu YS; Xu TM; Cui MH
    Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.
    Freedman RS; Platsoucas CD
    Cancer Treat Res; 1996; 82():115-46. PubMed ID: 8849947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian Cancer Immunotherapy: Turning up the Heat.
    Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
    Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
    Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minireview: Regulatory T Cells and Ovarian Cancer.
    Singh M; Loftus T; Webb E; Benencia F
    Immunol Invest; 2016 Nov; 45(8):712-720. PubMed ID: 27420920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models.
    Perales-Puchalt A; Wojtak K; Duperret EK; Yang X; Slager AM; Yan J; Muthumani K; Montaner LJ; Weiner DB
    Mol Ther; 2019 Feb; 27(2):314-325. PubMed ID: 30554854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.